Abstract:Background: Pancreatic ductal adenocarcinoma (PDAC) is ranked as the second leading cause of cancer-related mortality with a 5-year survival rate of merely 12%. The complexity of PDAC lies in its intrinsic resistance to treatment, attributable to the desmoplastic tumor microenvironment, characterized by an abundance of tumor-promoting extracellular matrix (ECM) and stromal cells. We hypothesize that Discoidin Domain Receptors (DDR), members of the receptor tyrosine kinase family known for their affinity to fibrillar collagens within the ECM, play an important role in promoting PDAC growth and progression. While several drugs targeting DDR proteins have been developed, no inhibitors to DDR proteins are specific or approved for PDAC treatment, thus necessitating the development of novel therapeutic interventions. Methods. A comprehensive high-throughput screening approach employing small molecule inhibitors was executed to identify authentic inhibitors targeting DDR. Subsequently, a rigorous evaluation of specificity of these small molecules was conducted through structural activity relationship (SAR) analyses and reference-based assessments. The efficacy of candidate inhibitors was assessed through functional assays, while mechanistic insights were gleaned using a multifaceted approach, including RNA-seq, real-time PCR, western blot analysis, in vivo experimentation, and Phospho-Receptor Tyrosine Kinase (RTK) profiling to discern any unintended off-target effects. Results: Using an unbiased screening approach, we identified 13 inhibitors that specifically target DDR. SAR studies and cellular thermal shift assay validated CIDD-0108633 (8633) as a bona fide DDR2 inhibitor. Functional assays and RNA-seq analyses demonstrated 8633's capacity to inhibit PDAC growth, metastatic potential, and expression of DNA replication, cell-cycle, and DNA damage repair genes. Combination therapy of 8633 with gemcitabine synergistically reduced PDAC cell viability and metastatic potential. Mechanistic studies revealed the role of ABC transporters in mediating gemcitabine resistance. RTK profiling shows moderate kinase selectivity. In vivo studies affirmed its antitumor effects. Conclusions: The results indicate that the selective inhibition of DDR with small molecule inhibitors suppresses PDAC cell growth and progression, implying that DDR inhibitors have the potential to be developed as safe and efficacious therapeutics for the treatment of pancreatic cancers. Citation Format: Trong Phat Do, Jack Prochnau, Prabhakar Pitta Venkata, Sajid Khan, Santosh Timilsina, Deepika Singh, Daisy Medina, Radhika Amaradhi, Daohong Zhou, Matthew Hart, Stanton McHardy, Manjeet Rao. Small molecule inhibitor targeting DDR represents a novel therapeutic strategy for the treatment of pancreatic ductal adenocarcinoma (PDAC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2904.

2-Amino-2,3-dihydro-1h-indene-5-carboxamide-based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy

Discovery and Optimization of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl)-ethynyl)benzamides As Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (ddr1) Inhibitors

Design, synthesis, and biological evaluation of novel discoidin domain receptor inhibitors for the treatment of lung adenocarcinoma and pulmonary fibrosis

Discovery Of 4-Amino-1h-Pyrazolo [3,4-D] Pyrimidin Derivatives As Novel Discoidin Domain Receptor 1 (Ddr1) Inhibitors

Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-n-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide As a Dual Inhibitor of Discoidin Domain Receptors 1 and 2

Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Discovery of Pyrazolo[3,4- d ]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation

Structure-Based Design of Tetrahydroisoquinoline-7-Carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Design And Optimization Of 3 '-(Imidazo[1,2-Alpha]Pyrazin-3-Yl)-[1,1 '-Biphenyl]-3-Carboxamides As Selective Ddr1 Inhibitors

Abstract 2904: Small molecule inhibitor targeting DDR represents a novel therapeutic strategy for the treatment of pancreatic ductal adenocarcinoma (PDAC)

Identification of Ureidocoumarin-Based Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors via Drug Repurposing Approach, Biological Evaluation, and In Silico Studies

The Role of DDR1 in Cancer and the Progress of Its Selective Inhibitors

Discoidin Domain Receptor 1 As a Potent Therapeutic Target in Solid Tumors

Research progress of DDR1 inhibitors in the treatment of multiple human diseases

Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors

Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.

Inhibition of tumor–microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain

Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies

Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β1-integrin Emerges as a Key Factor for Breast Cancer Chemosensitization upon Collagen Type 1 Binding

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Dithiocarbamate Moiety As Novel FAK Inhibitors with Antitumor and Anti-Angiogenesis Activities.